ExxonMobil has reversed the week-ago selloff in full, with the stock gaining 2.4% this week to close at $164.55 — clawing back almost exactly what the prior note flagged as lost ground and putting the stock back within striking distance of the $169.68 consensus mean target.
The recovery is broad-based rather than XOM-specific. The entire energy complex has turned, with APA — which led the prior week's damage — bouncing hardest at 7.1% on the week. CVX added 5.6%, CHRD gained 6.9%, and even the slower-moving names like COP and OXY posted 3–4% advances. The breadth of the recovery suggests macro sentiment has shifted rather than any single company-level catalyst — crude consolidation giving way to renewed risk appetite across integrated majors and pure-play E&Ps alike.
Positioning reinforces the bullish shift. Short interest has continued the retreat flagged last week — bears have now covered roughly 22% of their positions over the past month, with SI falling to just 0.83% of the free float, around 34.9 million shares. That is close to the lowest short conviction reading in the 30-day window. Borrow conditions confirm no meaningful counter-pressure: cost to borrow has eased to 0.30%, down sharply from 0.49% a week ago, and availability remains fully loose — the lending pool is nowhere near stressed, with shares to borrow vastly exceeding demand. The ORTEX short score has drifted lower too, from 30.6 in mid-August to 29.3 today, pointing to a market where bearish conviction on this name is quietly deflating.
Options positioning is close to neutral. The put/call ratio is running at 0.72, almost exactly in line with its 20-day average of 0.71, making the z-score effectively flat. There is no notable skew toward either downside protection or aggressive call buying — the options market is neither braced for a drop nor leaning into the recovery with conviction. The 52-week range on the PCR spans 0.47 to 0.90, so the current reading sits near the middle, without a directional signal.
The Street's view is broadly constructive but calibrated. Morgan Stanley raised its target to $177 on August 19, maintaining its Overweight rating, while Barclays trimmed to $177 from $182 — also Overweight — suggesting high conviction on direction but slightly trimmed ambition on the multiple. TD Cowen lifted to $168 earlier in August. Against those, BofA downgraded to Neutral in late July even as it nudged its target to $158, and Piper Sandler assumed coverage at Neutral with the same $158 target. The net picture is a Street that still leans positive — the consensus sits around $169 — but with a meaningful neutral bloc anchored near current prices. The bull case rests on Guyana and Permian production growth; the bear case flags refining margin risk and chemicals feedstock challenges. At 14.2x trailing earnings and 7.7x EV/EBITDA, valuation is not stretched for the integrated major category. The dividend factor score ranks in the 87th percentile of the universe, reflecting the company's consistent yield profile. Q3 earnings are due October 9, and the prior quarter's reaction — a 1.2% one-day drop — is a reminder that even a beat can struggle to move a stock trading close to full value.
The October 9 print is now the clearest near-term focus: whether the Guyana Liza Unity FPSO production suspension flagged in the prior note has been resolved, and whether the Permian ramp sustains the upstream volume story that underpinned the Q2 beat.
See the live data behind this article on ORTEX.
Open XOM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
